NOVAVAX INC (NVAX): M&A transaction — Novavax completes $200M sale of Czech manufacturing campus to Novo Nordisk

NOVAVAX INC

Total purchase price $200M; $180M cash at close, $10M paid Sept 2024, $10M escrow for 12 months.
Seller also received ~$2.6M reimbursement for operating costs between Dec 3 and closing.
Novavax sold its Bohumil, Jevany facility including land, movable assets, contracts, and employees.
Transaction closed Dec 30, 2024; Novo Nordisk Production Czech s.r.o. is the purchaser.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

NOVAVAX INC completed a disposition involving Novo Nordisk Production Czech s.r.o. for $200 million and the assumption by the Purchaser of liabilities (closed 2024-12-30).

Action: disposition
Counterparty: Novo Nordisk Production Czech s.r.o.
Consideration: $200 million and the assumption by the Purchaser of liabilities
Closing: 2024-12-30

Exact text from the filing

(iii) certain employees currently providing services related to the Transferred Assets (the “Transferred Employees”). The total purchase price for the Facility was $200 million and the assumption by the Purchaser of liabilities (on a look-forward basis) pertaining to the Transferred Assets, Transferred Contracts and Transferred Employees. On the closing

View on SEC.gov

30 m&a transactions filed in the last 30 days. Browse all m&a transactions →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-24-132569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.